1. AHFS Drug Information (2009) BOTOX®. Retrieved 2 Sep 2009, from
http://ashp.org/ahfs/
index.cfm
2. Alimi Q, Hascoet J, Manunta A, Kammerer-Jacquet S, Verhoest G, Brochard C et al (2018) Reliability of urinary cytology and cystoscopy for the screening and diagnosis of bladder cancer in patients with neurogenic bladder: a systematic review. Neurourol Urodyn 37:916–925.
https://doi.org/10.1002/nau.23395
3. American Urological Association (2014) White paper on catheter-associated urinary tract infections: definitions and significance in the urologic patient 2014. Downloaded from
https://www.aua-
net.org/common/pdf/education/clinical-guidance/Catheter-Associated-Urinary-Tract-
Infections-WhitePaper.pdf
. On 29 June 2015
4. American Urological Association (2016) White paper on Non-neurogenic chronic urinary retention: consensus definition, management strategies, and future opportunities.
5. Barendrecht MM, Oelke M, Laguna MP, Micheal MC (2007) Is the use of parasympathomimetics for treating an underactive bladder evidence based? BJU Int 99:749–752